TG Therapeutics competitorsClear all

TG Therapeutics's top competitors include Ironwood Pharmaceuticals, Biogen, Reata Pharmaceuticals and MyoKardia.
TG Therapeutics
TG Therapeutics
TG Therapeutics is a biopharmaceutical company, which develops agents for the treatment of hematologic malignancies and autoimmune disorders.
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, an entrepreneurial pharmaceutical company, develops drugs for gastrointestinal and cardiovascular diseases.
Biogen
Biogen
Biogen is a biopharmaceutical company that discovers, develops and delivers innovative therapies for people living with serious neurological and neurodegenerative diseases.
Reata Pharmaceuticals
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company focused on translating innovative science into breakthrough medicines for intractable diseases.
MyoKardia
MyoKardia
MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.
Founding Date
Founding Date
1993
Founding Date
N/A
Founding Date
1978
Founding Date
2002
Founding Date
2012
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
New York, US HQ
Locations
Cambridge, US HQ
Boston, US
Locations
Cambridge, US HQ
Vicente López, AR
North Ryde, AU
Wien, AT
Machelen, BE
São Paulo, BR
Mississauga, CA
see more
Locations
Plano, US HQ
Irving, US
Plano, US
Locations
South San Francisco, US HQ
Brisbane, US
Employees
Employees
15314% increase
Employees
31738% decrease
Employees
7,4005% decrease
Employees
22079% increase
Employees
23542% increase
Valuation ($)
Valuation ($)
3.4 b
Valuation ($)
1.5 b
Valuation ($)
40.8 b
Valuation ($)
3.9 b
Valuation ($)
11.9 b
Twitter followers
Twitter followers
1.8 k
Twitter followers
3.6 k
Twitter followers
34.4 k
Twitter followers
993
Twitter followers
1.1 k
Number of tweets (last 30 days)
Number of tweets (last 30 days)
7
Number of tweets (last 30 days)
2
Number of tweets (last 30 days)
50
Number of tweets (last 30 days)
22
Number of tweets (last 30 days)
9
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
19
Average likes per tweet (last 30 days)
4
Average likes per tweet (last 30 days)
11.1
Average likes per tweet (last 30 days)
6.6
Average likes per tweet (last 30 days)
8.4
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
100%
Alexa Website Rank
Alexa Website Rank
331552
Alexa Website Rank
313890
Alexa Website Rank
254464
Alexa Website Rank
365810
Alexa Website Rank
239431
Employee Rating
Employee Rating
N/A
Employee Rating
3.9
Employee Rating
3.9
Employee Rating
4
Employee Rating
4.2

Financial

Revenue (est.)
Revenue (est.)
$152k (FY, 2019)
Revenue (est.)
$428.4m (FY, 2019)
Revenue (est.)
$14.4b (FY, 2019)
Revenue (est.)
$26.5m (FY, 2019)
Revenue (est.)
N/A
Cost of goods
Cost of goods
N/A
Cost of goods
$23.9m (FY, 2019)
Cost of goods
$2b (FY, 2019)
Cost of goods
N/A
Cost of goods
N/A
Gross profit
Gross profit
N/A
Gross profit
$404.5m (FY, 2019)
Gross profit
$12.4b (FY, 2019)
Gross profit
N/A
Gross profit
N/A
Net income
Net income
($172.9m) (FY, 2019)
Net income
$21.5m (FY, 2019)
Net income
$5.9b (FY, 2019)
Net income
($290.2m) (FY, 2019)
Net income
($276.2m) (FY, 2019)

Operating

Patents (US)
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
21 (FY, 2019)
Patents (US)
N/A
Patents (US)
2 (FY, 2018)
Patents Issued
Patents Issued
N/A
Patents Issued
N/A
Patents Issued
34 (FY, 2019)
Patents Issued
240 (FY, 2016)
Patents Issued
N/A
Phase I Trials Products
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
11 (Q2, 2020)
Phase I Trials Products
2 (FY, 2016)
Phase I Trials Products
1 (FY, 2018)
Phase II Trials Products
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
10 (Q2, 2020)
Phase II Trials Products
4 (FY, 2016)
Phase II Trials Products
2 (FY, 2018)
Phase III Trials Products
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
6 (Q2, 2020)
Phase III Trials Products
1 (FY, 2016)
Phase III Trials Products
1 (FY, 2018)

Funding

Total funding raised
Total funding raised
$ 25m
Total funding raised
$ 609m
Total funding raised
N/A
Total funding raised
$ 468.9m
Total funding raised
$ 98m
For sources of this data, please see the company profile

View company profiles

Ironwood Pharmaceuticals
HQ
Cambridge, US
Employees
317↓ 38% decrease

Ironwood Pharmaceuticals, an entrepreneurial pharmaceutical company, develops drugs for gastrointestinal and cardiovascular diseases.

View company
Biogen
HQ
Cambridge, US
Employees
7,400↓ 5% decrease

Biogen is a biopharmaceutical company that discovers, develops and delivers innovative therapies for people living with serious neurological and neurodegenerative diseases.

View company
Reata Pharmaceuticals
HQ
Plano, US
Employees
220

Reata Pharmaceuticals is a biopharmaceutical company focused on translating innovative science into breakthrough medicines for intractable diseases.

View company
MyoKardia
HQ
South San Francisco, US
Employees
235↑ 42% increase

MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.

View company